General Information of Drug (ID: DMBJU2X)

Drug Name
ISIS 116654 Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
TTD Drug ID
DMBJU2X

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
aloisine A DM5U1LN Discovery agent N.A. Investigative [2]
CHIR-98014 DMVEBT6 Discovery agent N.A. Investigative [3]
indirubin deriv. 8a DMYLVQF Discovery agent N.A. Investigative [4]
LEUCETTAMINE B DMFQEWM Discovery agent N.A. Investigative [5]
ISIS 116625 DMIJES1 Discovery agent N.A. Investigative [1]
ISIS 116648 DMUOB3S Discovery agent N.A. Investigative [1]
ISIS 116632 DMW2Q4T Discovery agent N.A. Investigative [1]
ISIS 116631 DM2X5RT Discovery agent N.A. Investigative [1]
ISIS 116670 DM9R51M Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GSK3A messenger RNA (GSK3A mRNA) TTQWAU1 GSK3A_HUMAN Not Available [1]

References

1 US patent application no. 6,316,259, Antisense inhibition of glycogen synthase kinase 3 alpha expression.
2 Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
3 Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
4 Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem. 2004 Feb 12;47(4):935-46.
5 Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors. Eur J Med Chem. 2010 Feb;45(2):805-10.